Suppliers and packagers for BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Lgm Pharma	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE	aspirin; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	075231	ANDA	Breckenridge Pharmaceutical, Inc.	51991-074-01	100 CAPSULE in 1 BOTTLE, PLASTIC (51991-074-01)	2009-05-01
Lgm Pharma	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE	aspirin; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	075231	ANDA	Breckenridge Pharmaceutical, Inc.	51991-074-05	500 CAPSULE in 1 BOTTLE, PLASTIC (51991-074-05)	2009-05-01
Lgm Pharma	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE	aspirin; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	075231	ANDA	Bryant Ranch Prepack	63629-2952-1	30 CAPSULE in 1 BOTTLE (63629-2952-1)	2009-05-01

Butalbital, Aspirin, Caffeine, and Codeine Phosphate: Key Supply Chain Analysis

Last updated: February 19, 2026

This report details the global suppliers for the active pharmaceutical ingredients (APIs) butalbital, aspirin, caffeine, and codeine phosphate, critical components in combination analgesic products. Understanding these suppliers is vital for pharmaceutical manufacturers assessing supply chain resilience, cost optimization, and regulatory compliance. The analysis focuses on identified manufacturers and their geographical distribution, highlighting potential concentration risks and alternative sourcing options.

Who are the Primary Manufacturers of Butalbital API?

Butalbital, a barbiturate, is a central nervous system depressant used in combination pain relievers. Its production is concentrated among a limited number of manufacturers globally.

• European Union: Several manufacturers based in the EU hold significant market share. These include companies in Germany and Spain, which have historically been major producers of barbiturates. For example, Rottendorf Pharma GmbH (Germany) is a known supplier.
• India: The Indian pharmaceutical sector also contributes to global butalbital supply. Companies like Granules India Ltd. have capabilities in producing controlled substances, including butalbital.
• United States: While domestic production exists, it is less prevalent compared to EU and Indian manufacturers. Mallinckrodt Pharmaceuticals has been a historical producer.

The market for butalbital is subject to stringent regulatory oversight due to its controlled substance status. This often limits the number of new entrants and perpetuates the dominance of established producers.

Which Companies Supply Aspirin API?

Aspirin (acetylsalicylic acid) is a widely used nonsteroidal anti-inflammatory drug (NSAID). Its production is largely commoditized, with numerous global suppliers.

• China: China is a dominant global supplier of aspirin API, with numerous manufacturers. Key players include Zhejiang NHU Company Ltd. and Anqiu Zhongxing Pharmaceutical Co., Ltd. These companies benefit from large-scale production capabilities and competitive pricing.
• India: India also has a substantial aspirin API manufacturing base. Companies like Lasa Supergenerics Limited and Granules India Ltd. are active in this market.
• Europe: Several European countries, notably Germany, continue to produce aspirin API, often focusing on higher-purity grades or specialized formulations. Lanxess AG has been a significant producer.

The high volume and broad application of aspirin lead to a generally stable and competitive supply market, though raw material price fluctuations (salicylic acid) can impact cost.

Where are the Main Suppliers of Caffeine API Located?

Caffeine, a stimulant, is an essential component in many analgesic formulations to enhance pain relief and counteract sedative effects.

• China: China leads in global caffeine API production. Major suppliers include Shanghai Bio-Pharm Technology Co., Ltd. and Hebei Bangchi Biotechnology Co., Ltd. These companies leverage economies of scale to offer competitive pricing.
• India: Indian manufacturers also play a significant role. Siddhi Vinayak Synethem Pvt. Ltd. and Alkali Chemical Corporation of India are noted producers.
• Germany: German companies, such as Tchibo GmbH (though primarily a coffee company, it has pharmaceutical-grade caffeine operations), are also part of the supply chain, often catering to specific quality standards.
• United States: While less dominant, some US-based companies are involved in caffeine production, particularly for specialized or high-purity applications.

The caffeine API market is generally well-supplied, with significant capacity available from multiple regions.

Who are the Principal Manufacturers of Codeine Phosphate API?

Codeine phosphate is an opioid analgesic, a controlled substance requiring strict regulatory compliance for its manufacturing and distribution.

• United States: Historically, the United States has been a major producer of opioid APIs, including codeine. Mallinckrodt Pharmaceuticals has been a key player. However, regulatory pressures and market shifts have influenced production levels.
• India: India has emerged as a significant source for codeine phosphate API. Companies like Jubilant Pharmova Limited and Orchid Pharma Ltd. are involved in the production of opioid derivatives.
• Europe: A few European countries, such as Spain and the UK, house manufacturers capable of producing codeine phosphate, often under strict regulatory frameworks. Alcaliber S.A. (Spain) is a recognized producer.
• Australia: Chemsupply Pty Ltd. in Australia is also listed as a supplier.

The supply of codeine phosphate is tightly controlled due to its Schedule II (US) or equivalent international classification. This restricts the number of licensed manufacturers and can lead to price volatility and supply chain vulnerabilities. The sourcing of raw opium and strict adherence to international drug control treaties are critical factors.

What is the Geographical Distribution of These Combined API Suppliers?

The suppliers for butalbital, aspirin, caffeine, and codeine phosphate are geographically distributed, with significant concentrations in specific regions that present both opportunities and risks.

Global API Supplier Distribution Summary:

API	Primary Manufacturing Regions	Key Countries	Notes
Butalbital	Europe, Asia	Germany, Spain, India	Highly regulated; limited number of producers.
Aspirin	Asia, Europe, North America	China, India, Germany, USA	Commoditized; high volume, competitive pricing.
Caffeine	Asia, Europe	China, India, Germany	Well-supplied market; diverse global capacity.
Codeine Phosphate	North America, Asia, Europe	USA, India, Spain, UK	Highly regulated (controlled substance); supply chain sensitivity.

• Asia (Primarily China and India): These regions are dominant suppliers for aspirin and caffeine, benefiting from large-scale production infrastructure and cost advantages. India also plays a crucial role in butalbital and codeine phosphate, particularly for regulated APIs. This concentration offers scale but raises concerns about geopolitical risks, quality control standardization, and intellectual property protection.
• Europe: European manufacturers, particularly in Germany and Spain, remain important for butalbital and codeine phosphate, often associated with high-quality standards and adherence to strict regulatory requirements (e.g., EU GMP). They also contribute to aspirin supply. This region offers reliability but typically at a higher cost.
• North America (Primarily USA): The US has historical strength in opioid API production, including codeine phosphate, and contributes to aspirin and caffeine supply. However, regulatory changes and manufacturing cost structures influence its current market position for these APIs.

How Do Regulatory Requirements Impact the Supply Chain?

Regulatory requirements are a primary driver of supply chain structure and risk for these APIs.

• Controlled Substances: Butalbital and codeine phosphate are classified as controlled substances in many jurisdictions (e.g., DEA Schedule III for butalbital combinations in the US, Schedule II for codeine in the US). This mandates stringent licensing for manufacturers, distributors, and importers, rigorous record-keeping, and security measures to prevent diversion. Compliance with international bodies like the International Narcotics Control Board (INCB) is also critical for codeine.
• Good Manufacturing Practices (GMP): All API manufacturers must adhere to GMP standards, ensuring product quality, purity, and consistency. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and India's Central Drugs Standard Control Organization (CDSCO) conduct inspections and require detailed documentation. Compliance failures can lead to import alerts or manufacturing shutdowns.
• Chemical Precursors: The production of some APIs may involve regulated chemical precursors, adding another layer of compliance.
• Environmental Regulations: Manufacturing processes are subject to environmental regulations concerning waste disposal and emissions, which can impact operational costs and site selection.

These regulations create significant barriers to entry, concentrating production among established and compliant entities. They also necessitate robust quality agreements and auditing protocols for pharmaceutical formulators sourcing these APIs.

What are the Potential Supply Chain Risks and Mitigation Strategies?

The supply chain for butalbital, aspirin, caffeine, and codeine phosphate faces several risks.

Key Supply Chain Risks:

• Geopolitical Instability: Concentration of production in specific countries, particularly China and India, exposes the supply chain to risks from trade disputes, political unrest, or natural disasters in those regions.
• Regulatory Changes: Sudden changes in drug scheduling, import/export controls, or GMP enforcement can disrupt supply. The opioid crisis has led to increased scrutiny and tighter controls on codeine phosphate production and distribution.
• Quality Control Failures: Non-compliance with GMP standards by any supplier can lead to product recalls, market withdrawals, and significant reputational damage for the pharmaceutical company.
• Price Volatility: Fluctuations in raw material costs (e.g., petrochemicals for aspirin synthesis, opium for codeine) and increased regulatory compliance costs can impact API pricing.
• Limited Supplier Base for Controlled Substances: The restricted number of licensed manufacturers for butalbital and codeine phosphate creates a bottleneck and increases vulnerability to single-source disruptions.

Mitigation Strategies:

• Supplier Diversification: Actively qualify and maintain relationships with multiple suppliers across different geographical regions for each API. Prioritize suppliers in stable political and regulatory environments.
• Dual Sourcing and Inventory Management: Implement dual sourcing strategies for critical APIs, especially controlled substances. Maintain strategic safety stock levels to buffer against short-term supply interruptions.
• Robust Quality Audits and Agreements: Conduct thorough on-site audits of all API suppliers. Establish comprehensive quality agreements that clearly define specifications, change control procedures, and incident reporting.
• Supply Chain Monitoring: Utilize market intelligence and real-time tracking to monitor geopolitical events, regulatory developments, and supplier performance.
• Long-Term Contracts: Negotiate long-term supply agreements with key suppliers to secure volume, pricing, and commitment, especially for APIs with limited manufacturers.
• Regulatory Foresight: Proactively monitor proposed regulatory changes in key markets and engage with regulatory bodies to understand potential impacts.
• Vertical Integration (Selective): For highly critical or strategically important APIs, consider backward integration or strategic partnerships to gain more control over the supply chain.

Key Takeaways

The global supply of butalbital, aspirin, caffeine, and codeine phosphate is characterized by regional concentrations and significant regulatory oversight, particularly for butalbital and codeine phosphate due to their controlled substance status. China and India dominate the high-volume, less regulated APIs like aspirin and caffeine, while Europe and the US retain important roles for more specialized or controlled APIs. Diversification of suppliers across geographies, robust quality management systems, and proactive regulatory monitoring are essential for mitigating supply chain risks.

FAQs

What is the primary risk associated with sourcing butalbital and codeine phosphate?

The primary risk is the stringent regulatory environment for controlled substances, which limits the number of manufacturers and increases the potential for supply disruptions due to compliance issues or diversion controls.

How can a pharmaceutical company reduce its reliance on Chinese API suppliers for aspirin?

Companies can mitigate reliance by identifying and qualifying alternative suppliers in India, Europe (e.g., Germany), or North America, even if at a potentially higher cost, and by negotiating diversified supply agreements.

What are the implications of the opioid crisis on codeine phosphate API sourcing?

The opioid crisis has resulted in increased regulatory scrutiny, tighter production quotas, enhanced security measures, and potential limitations on the availability of codeine phosphate API, requiring manufacturers to demonstrate strict compliance and accountability.

Are there significant differences in quality standards between API suppliers in Asia and Europe?

While GMP standards are universal, there can be perceived and actual differences in the rigor of enforcement and the typical quality profiles. European suppliers often emphasize adherence to pharmacopeial standards (e.g., EP) and are subject to continuous inspection by agencies like the EMA, potentially leading to higher assurance for certain high-purity or complex APIs.

What steps should be taken if a key API supplier experiences a manufacturing disruption?

Immediate steps include activating contingency plans, assessing inventory levels, engaging with secondary or alternative qualified suppliers, and communicating transparently with regulatory authorities and downstream customers regarding potential delays or product availability impacts.